2024
Treatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib
Robinson N, Canavan M, Zhan P, Udelsman B, Pathak R, Boffa D, Goldberg S. Treatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib. Clinical Lung Cancer 2024 PMID: 39462746, DOI: 10.1016/j.cllc.2024.09.006.Peer-Reviewed Original ResearchNon-small cell lung cancerEGFR-mutant non-small cell lung cancerFirst-line osimertinibContinuation of osimertinibImmune checkpoint inhibitorsTyrosine kinase inhibitorsCell lung cancerRetrospective cohort studyOverall survivalTreatment regimensLung cancerAdvanced epidermal growth factor receptorAssociated with increased PFSAssociated with superior PFSSecond-line treatment regimenEGFR exon 19 deletionRetrospective cohort study of patientsEGFR tyrosine kinase inhibitorsAssociated with prolonged survivalCohort study of patientsSecond-line treatment regimensExon 19 deletionFirst-line therapyEpidermal growth factor receptorFirst-line treatment
2023
Respect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy
Li A, Canavan M, Ermer T, Maduka R, Zhan P, Pichert M, Boffa D, Blasberg J. Respect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy. The Annals Of Thoracic Surgery 2023, 117: 163-171. PMID: 37774762, DOI: 10.1016/j.athoracsur.2023.09.023.Peer-Reviewed Original ResearchConceptsLower bilobectomyLeft pneumonectomyLung cancerMiddle lobeRight-sided lung cancerCox proportional hazards modelThirty-day morbidityTotal lung functionPreoperative risk stratificationThoracic Surgeons databaseProportional hazards modelPneumonectomy patientsUpper bilobectomyBronchial involvementPerioperative mortalityPerioperative riskPerioperative variablesPatient demographicsPulmonary resectionRight pneumonectomySecondary outcomesLung functionMiddle lobectomyPrimary outcomePropensity matchingOverall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery
Udelsman B, Canavan M, Zhan P, Ely S, Park H, Boffa D, Mase V. Overall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery. Journal Of Thoracic And Cardiovascular Surgery 2023, 167: 822-833.e7. PMID: 37500052, DOI: 10.1016/j.jtcvs.2023.07.021.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic body radiotherapyStage I non-small cell lung cancerLow-comorbidity patientsCell lung cancerOverall survivalSurgical managementLung cancerSurgical resectionBody radiotherapyClinical stage I non-small cell lung cancerEarly-stage non-small cell lung cancerPropensity score-matched cohortPropensity score-matched patientsPropensity score-matched analysisEarly-stage lung cancerLong-term OSNational Cancer DatabaseProportion of patientsCancer DatabasePatientsSBRT patientsSurgeryCancerMortality
2022
OA11.03 Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Non-Small Cell Lung Cancer: A Marker of Better Prognosis
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Boffa D. OA11.03 Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Non-Small Cell Lung Cancer: A Marker of Better Prognosis. Journal Of Thoracic Oncology 2022, 17: s29-s30. DOI: 10.1016/j.jtho.2022.07.056.Peer-Reviewed Original Research
2020
The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM).
Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM). Journal Of Clinical Oncology 2020, 38: 2-2. DOI: 10.1200/jco.2020.38.29_suppl.2.Peer-Reviewed Original ResearchOncology Care ModelDrug costsCancer CenterLung cancerEpisode costsMean MedicareYale Cancer CenterClinical trial participationSystemic cancer therapyPart D drug costsCancer therapyLower drug costsCommon cancer typesChi-square testPayment modelsClinical factorsNovel cancer therapiesTrial participationOvarian cancerPatient episodesNovel therapiesCare modelCTR groupPharmaceutical costsAlternative payment modelsThe impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM).
Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM). Journal Of Clinical Oncology 2020, 38: e19367-e19367. DOI: 10.1200/jco.2020.38.15_suppl.e19367.Peer-Reviewed Original ResearchOncology Care ModelDrug costsMean MedicareYale Cancer CenterMean drug costClinical trial participationSystemic cancer therapyLower drug costsCommon cancer typesChi-square testValue-based payment modelsPayment modelsClinical factorsCancer CenterTrial participationLung cancerEpisode costsCare modelCTR groupAlternative payment modelsCancer typesMean differenceCancer therapyCareEpisodesEnd-of-life (EOL) trajectories among older adults dying with lung cancer (LC).
Davidoff A, Canavan M, Wang S, Prsic E, Saphire M, Presley C. End-of-life (EOL) trajectories among older adults dying with lung cancer (LC). Journal Of Clinical Oncology 2020, 38: e24008-e24008. DOI: 10.1200/jco.2020.38.15_suppl.e24008.Peer-Reviewed Original ResearchPalliative care servicesHospital referral regionsLung cancerCancer decedentsCare intensityNon-Hispanic whitesCD careLine therapyHospice enrollmentSEER-MedicareIntensive careHospice useOlder decedentsPhysician preferenceHigh riskHospice careMultinomial logistic regressionReferral regionsMedicare decedentsHigher ageCare servicesHealth statusLogistic regressionDecedentsHospiceThe association between initial chemotherapy treatment timing, intensity, and end-of-life (EOL) care trajectory among older adults with advanced stage lung cancer (aLC).
Presley C, Shahzad H, Canavan M, Prsic E, Saphire M, Wang S, Davidoff A. The association between initial chemotherapy treatment timing, intensity, and end-of-life (EOL) care trajectory among older adults with advanced stage lung cancer (aLC). Journal Of Clinical Oncology 2020, 38: e24009-e24009. DOI: 10.1200/jco.2020.38.15_suppl.e24009.Peer-Reviewed Original ResearchAdvanced-stage lung cancerDoublet chemotherapyEOL groupOlder adultsIntensity groupInitial chemotherapy regimenInitial chemotherapy treatmentPlatinum-based doubletsPlatinum-doublet chemotherapyFirst-line therapyUse of chemotherapyMajority of patientsEOL care preferencesStage lung cancerMain outcome measuresNon-Hispanic whitesMedicare registryChemotherapy regimenLine therapyCisplatin chemotherapyLung cancerChemotherapy treatmentAge 66Outcome measuresCare trajectories
2019
Patterns of palliative symptom management (PSM) medication use at end-of-life (EoL) among Medicare beneficiaries with advanced lung cancer (advLC).
Davidoff A, Prsic E, Saphire M, Canavan M, Wang S, McCorkle R, Presley C. Patterns of palliative symptom management (PSM) medication use at end-of-life (EoL) among Medicare beneficiaries with advanced lung cancer (advLC). Journal Of Clinical Oncology 2019, 37: 130-130. DOI: 10.1200/jco.2019.37.27_suppl.130.Peer-Reviewed Original ResearchMedication useEoL-1Medication receiptPoor patient-provider communicationAdvanced lung cancerHigh symptom burdenPatient demographic characteristicsPatient-provider communicationAge 77 yearsMedicare/MedicaidRace/ethnicity groupsNon-Hispanic whitesNausea/ vomitingSymptom burdenHospice enrollmentSymptom reliefConcurrent radiationSEER-MedicareOutpatient settingParenteral medicationsLung cancerMedicare beneficiariesPatientsLogistic regressionOlder adults